HM Company News

US based psychiatric provider Acadia Healthcare has acquired Partnerships in Care (PiC) from its private equity owners Cinven for approximately $660m (£393m).

    Sandie Foxall-Smith, CEO of The Regard Group, is stepping down after five years in the post. Regard was recently acquired by AMP Capital. Global Head...

MedicX Fund, the investor in primary healthcare properties in the UK announced in its interim management statement for the period from 1 April 2012 to 8 August 2012, that its portfolio was valued at 30 June at £286.1 million reflecting a net initial yield of 5.87%. This is unchanged from March 2012, and compares favourably it says with the weighted average fixed cost of drawn long term debt held by the company of 4.72%. Incorporating the June valuation, the unaudited adjusted net asset value at 30 June 2012 is estimated to be £166.3 million, equivalent to 64.7p per share compared with 65.5p per share at 31 March 2012.

Neurorehabiliation specialist Christchurch Court Holdings has reported a X leap in turnover to £5.1m.

Healthcare Market News (Company News) August 2001 University College London Hospitals NHS Trust (UCLH) has acquired the private Heart Hospital for £27.5m....

Healthcare Market News (Company News) June 2003 Match makes most of staffing business Match Healthcare Ltd, the former Sinclair Montrose business,...

BMI Healthcare has reported a 4.4% rise in revenue to £446.8m for the last six months thanks to continuing increases in NHS activity.

Assura Group Plc has announced a three-fold surge in pre-tax profits to £95.2m for the year ended 31 March 2017 on the back of...

US-owned mental health provider Cygnet Health has reported a 35% leap in revenue to £179.3m for the year ended 31 December 2016 as acquisitions...

Alliance Medical’s acquisition of IBA Molecular has been referred to the Competition Commission by the Office of Fair Trading (OFT). Alliance acquired the company in September 2013 in a move to secure the future UK production of the vital pharmaceutical that allows PET/CT scanning – Fluorodeoxyglucose 18F (FDG-18). The deal was supported by investors and the Department of Health and saw Alliance take on IBA Molecular’s FDG production facility, gaining a licensing agreement to supply Alliance PET/CT centres in Italy, Germany and Spain. IBA Molecular continued its other UK nuclear medicine manufacturing activities as well as its FDG business in the rest of Europe.